New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
January 11, 2017 – The FDA approved Genentech’s Esbriet (pirfenidone) oral tablets, for the treatment of idiopathic pulmonary fibrosis (IPF).
Download PDF
Return to publications
